Rank portfolio companies by risk adjusted progress
Rank stage-comparable portfolio companies by evidence-shrunk milestone value minus a CVaR downside penalty per cash consumed, with weak evidence explicitly unranked.
What it's for
Gives investors a transparent capital-efficiency ranking in which evidence quality and downside change priority instead of rewarding confident milestone narratives.
What you give it
Inputs split into evidence read from your connected systems, calibration your team owns, and numerical controls that affect precision but never the result's meaning.
| Field | Type | Role | Required |
|---|---|---|---|
| companies | array of objects (7 fields) ≥ 2 items | Evidence | Yes |
| max_detail_rows | integer ≥ 1, ≤ 500 | Numerical control | Optional |
| minimum_evidence_reliability | number ≥ 0, ≤ 1 | Your calibration | Optional |
| risk_aversion | number ≥ 0 | Your calibration | Optional |
| scenario_probabilities | array of number ≥ 2 items | Evidence | Yes |
| skeptical_prior_progress | number ≥ 0, ≤ 1 | Your calibration | Optional |
| tail_probability | number ≥ 0.001, ≤ 0.5 | Your calibration | Optional |
Each companies
record
| Field | Type | Required |
|---|---|---|
| achieved_milestone_weight | number (≥ 0) | Yes |
| additional_capital_required | number (≥ 0) | Yes |
| cash_consumed | number (> 0) | Yes |
| evidence_reliability | number (≥ 0, ≤ 1) | Yes |
| id | string (non-empty) | Yes |
| milestone_value_if_fully_achieved_scenarios | array of number (≥ 2 items) | Yes |
| total_milestone_weight | number (> 0) | Yes |
{
"companies": [
{
"achieved_milestone_weight": 8,
"additional_capital_required": 100000,
"cash_consumed": 1000000,
"evidence_reliability": 0.9,
"id": "company-a",
"milestone_value_if_fully_achieved_scenarios": [
1000000,
3000000,
5000000
],
"total_milestone_weight": 10
},
{
"achieved_milestone_weight": 9,
"additional_capital_required": 300000,
"cash_consumed": 1500000,
"evidence_reliability": 0.8,
"id": "company-b",
"milestone_value_if_fully_achieved_scenarios": [
-2000000,
4000000,
7000000
],
"total_milestone_weight": 10
}
],
"minimum_evidence_reliability": 0.5,
"risk_aversion": 1,
"scenario_probabilities": [
0.2,
0.5,
0.3
],
"skeptical_prior_progress": 0
} What you get back
This is the actual output of running the example above — computed by the same function the platform calls, not an illustration.
{
"assumptions": [
"Companies are stage-, window-, currency-, accounting-, milestone-, and scenario-comparable; milestone weights and fully-achieved value are governed before outcomes are inspected.",
"Evidence reliability is calibrated on resolved comparable claims, weak progress is shrunk to the skeptical prior, and scenario columns describe the same joint future across companies.",
"The declared ranking formula is evidence-adjusted milestone value minus a CVaR loss penalty per cash consumed; it is not causal attribution, valuation, company quality, an investment recommendation, or a person-level decision."
],
"company_diagnostics": [
{
"clears_evidence_gate": true,
"company_id": "company-a",
"cvar_net_milestone_value_loss": -620000,
"decision": "rank_eligible",
"evidence_adjusted_milestone_progress": 0.72,
"evidence_reliability": 0.9,
"expected_net_milestone_value": 2204000,
"observed_milestone_progress": 0.8,
"probability_negative_net_milestone_value": 0,
"rank": 1,
"risk_adjusted_net_milestone_value": 2824000,
"risk_adjusted_value_per_cash_consumed": 2.824
},
{
"clears_evidence_gate": true,
"company_id": "company-b",
"cvar_net_milestone_value_loss": 1740000,
"decision": "rank_eligible",
"evidence_adjusted_milestone_progress": 0.72,
"evidence_reliability": 0.8,
"expected_net_milestone_value": 2364000,
"observed_milestone_progress": 0.9,
"probability_negative_net_milestone_value": 0.2,
"rank": 2,
"risk_adjusted_net_milestone_value": 624000,
"risk_adjusted_value_per_cash_consumed": 0.416
}
],
"configuration": {
"minimum_evidence_reliability": 0.5,
"risk_aversion": 1,
"scenario_count": 3,
"skeptical_prior_progress": 0,
"tail_probability": 0.1
},
"decision": "risk_adjusted_progress_ranking_available", Truncated for display — the full payload is 53 lines.
How it works
Constrained optimization — Pick the best feasible option under real limits — budget, headcount, dependencies, capacity — rather than ranking a list and hoping it fits.
- 1 Freeze a stage-comparable cohort, milestone weights, cash and additional-capital perimeter, aligned fully-achieved milestone value scenarios, and reliability estimates calibrated on resolved comparable claims.
- 2 Shrink observed weighted progress toward the skeptical prior, translate it into net scenario value, subtract additional capital, penalize CVaR loss by the governed risk aversion, and divide by cash consumed.
- 3 Rank only companies clearing the evidence gate using the declared risk-adjusted value-per-cash formula, showing every component and leaving insufficient-evidence companies unranked.
Before you trust it
Every tool in the catalog ships with the conditions under which its answer is meaningful — and the conditions under which it should abstain instead of guessing.
Assumptions & guardrails
- Objectives use commensurable locally governed value units, constraints reflect real feasibility, and uncertainty covers plausible adverse inputs.
- Company stage, window, currency, accounting, milestone, cash, outcome maturity, and joint scenario definitions are comparable, and fully-achieved milestone values are governed independently of observed progress.
- The recommendation is optimal only for its stated objective, feasible set, evidence, and solver guarantee; it is not a universal management optimum.
- The ranking is a transparent model-conditional portfolio triage—not causal attribution, valuation, company quality, a cross-stage league table, investment advice, or a person-level decision.
Minimum evidence
- companies: at least 2 rows/items
- scenario_probabilities: at least 2 rows/items
How to validate it
Backtest the chosen action against simple feasible baselines on held-out scenarios, sweep costs/constraints/risk tolerance, and require constraint feasibility under adverse inputs.
Calibrating it to your org
Same for everyone
The mathematical kernel, validation rules, method version, and JSON output semantics are organization-independent; no tenant-trained coefficients or company benchmark is embedded in the function.
Specific to you
- outcome-mature weighted progress and resolved comparable claim reliability by company under one comparison window
- portfolio access boundary, stage/window/currency/accounting comparability, milestone taxonomy/weights, cash and capital perimeter, scenario identity/probabilities, skeptical prior, evidence gate, risk aversion, and tail definition
Calibration workflow
- 1 Define the management decision, target outcome, aggregate unit, privacy boundary, cadence, and prediction/intervention horizon for this organization.
- 2 Build a tenant-scoped historical cohort using only information available before each prediction or decision; preserve zero periods, censoring, assignment probabilities, and unresolved outcomes when the method requires them.
- 3 Estimate statistical parameters on training history, but obtain costs, utilities, risk tolerance, practical-effect thresholds, capacity, and policy constraints from accountable decision owners.
- 4 Validate on later time windows or held-out aggregate units at the deployment grain, against a simple baseline and the function-specific validation strategy.
- 5 Deploy only if the returned decision clears evidence, overlap, calibration, robustness, and guardrail checks; warning, unsupported, schema-gap, and fallback decisions are abstentions.
- 6 Monitor realized outcomes, data drift, coverage, and decision regret; recalibrate at a governed cadence or after a detected regime/definition change, never merely because a stakeholder dislikes the result.
Call it from your AI
You don't wire up 388 tools in your MCP client. The GitRevio MCP server exposes 18 tools, three of which let an agent search the catalog, read a tool's schema, and run it — so the assistant finds this one on its own.
gitrevio_capabilities_search
{ "q": "rank stagecomparable portfolio companies by evidenceshrunk" }
→ finds "rank_portfolio_companies_by_risk_adjusted_progress"
gitrevio_capability_describe
{ "capability_id": "rank_portfolio_companies_by_risk_adjusted_progress" }
→ returns the input schema and agent guidance shown on this page
gitrevio_capability_run
{ "capability_id": "rank_portfolio_companies_by_risk_adjusted_progress", "arguments": { ... } }
→ returns the result shown above Works in Claude Desktop, Claude Code, Cursor, Cline, Continue.dev, Goose and Aider. See the MCP server.
Related tools
Estimate portfolio company execution beta
Estimate company sensitivity to an external portfolio execution factor using company regressions, random-effects heterogeneity, empirical-Bayes shrinkage, uncertainty intervals, and systematic variance shares.
Stress test investment memo assumptions
Stress an investment memo's local value model by shrinking weak claims toward declared adverse values, pricing pairwise nonlinear interactions, and finding the first failure fraction along a joint adverse path.
Allocate budget with CVAR constraint
Maximize expected portfolio return while keeping probability-weighted loss CVaR below a finance-owned tail-risk ceiling across aligned joint scenarios.
Audit budget constraint binding
Audit whether a claimed budget constraint genuinely blocks value after dependency-feasible portfolio reallocation, separating current-plan inefficiency from scarcity with scenario CVaR and a discrete budget shadow price.
Audit financing term sheet integrity
Audit startup financing terms as exact share, price, proceeds and ownership identities: include pre-money option-pool increases and converting instruments in the pricing denominator, keep secondary purchases out of company cash and post-money share creation, reconcile primary issuance, post-money equity value and reported investor ownership, and retain evidence failures and impossible fees or secondary sales.
Audit fundraising pipeline integrity
Audit a fundraising pipeline as point-in-time evidence rather than CRM theater: reconstruct monotone stage events, terminal status and primary proceeds, retain open opportunities as censored, reject forecasts made after resolution, detect duplicate active investor accounts, and gate the portfolio on mature-forecast support, Brier loss and calibration gap.